Shots:
- Sangamo to receive $75M upfront within 30 days, $720M milestone payments including up to $420M in development milestones and up to $300M in commercial milestones plus royalties on sales of the product. Additionally, Sangamo to take care of certain research and manufacturing activities funded by Novartis
- Novartis to get exclusive license rights of ZFP-TFs for three genes including ASD and intellectual disability for neurodevelopmental disorders also holds an option to license Sangamo’s AAVs. The company will perform research activities, investigational new drug-enabling studies clinical development, related regulatory interactions, manufacturing and, global commercialization
- ZFP-TFs is a genome regulation technology delivered using AAVs and will be utilized by the partnering companies to upregulate, or activate, the expression of genes expressed in individuals with certain types of neurodevelopmental disorders
Click here to read full press release/ article | Ref: Businesswire | Image: Healthworld
